Logo image of TNXP

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

USA - NASDAQ:TNXP - US8902608392 - Common Stock

17 USD
-0.41 (-2.35%)
Last: 11/7/2025, 8:22:05 PM
16.95 USD
-0.05 (-0.29%)
After Hours: 11/7/2025, 8:22:05 PM
Fundamental Rating

3

Overall TNXP gets a fundamental rating of 3 out of 10. We evaluated TNXP against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TNXP as it has an excellent financial health rating, but there are worries on the profitability. TNXP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TNXP has reported negative net income.
TNXP had a negative operating cash flow in the past year.
TNXP had negative earnings in each of the past 5 years.
In the past 5 years TNXP always reported negative operating cash flow.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

TNXP has a Return On Assets (-43.46%) which is comparable to the rest of the industry.
TNXP has a better Return On Equity (-48.47%) than 66.42% of its industry peers.
Industry RankSector Rank
ROA -43.46%
ROE -48.47%
ROIC N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Gross Margin of TNXP (29.27%) is better than 73.51% of its industry peers.
TNXP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
TNXP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TNXP has been increased compared to 5 years ago.
The debt/assets ratio for TNXP has been reduced compared to a year ago.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

TNXP has an Altman-Z score of -1.78. This is a bad value and indicates that TNXP is not financially healthy and even has some risk of bankruptcy.
TNXP's Altman-Z score of -1.78 is in line compared to the rest of the industry. TNXP outperforms 51.49% of its industry peers.
TNXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.78
ROIC/WACCN/A
WACC8.91%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 7.53 indicates that TNXP has no problem at all paying its short term obligations.
TNXP has a Current ratio of 7.53. This is in the better half of the industry: TNXP outperforms 71.46% of its industry peers.
TNXP has a Quick Ratio of 7.22. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.22, TNXP is doing good in the industry, outperforming 70.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.53
Quick Ratio 7.22
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

TNXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.64%, which is quite impressive.
The Revenue for TNXP has decreased by -21.09% in the past year. This is quite bad
EPS 1Y (TTM)99.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.8%
Revenue 1Y (TTM)-21.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.51%

3.2 Future

TNXP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.99% yearly.
Based on estimates for the next years, TNXP will show a very strong growth in Revenue. The Revenue will grow by 118.28% on average per year.
EPS Next Y99.47%
EPS Next 2Y41.3%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year-10.16%
Revenue Next 2Y204.72%
Revenue Next 3Y118.28%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500M -1B -1.5B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNXP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNXP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as TNXP's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.3%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (11/7/2025, 8:22:05 PM)

After market: 16.95 -0.05 (-0.29%)

17

-0.41 (-2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners15.84%
Inst Owner Change29.15%
Ins Owners0.06%
Ins Owner Change3.33%
Market Cap149.09M
Revenue(TTM)9.83M
Net Income(TTM)-81.42M
Analysts82.5
Price Target69.02 (306%)
Short Float %20.38%
Short Ratio1.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.95%
Min EPS beat(2)-17.71%
Max EPS beat(2)13.8%
EPS beat(4)3
Avg EPS beat(4)46.48%
Min EPS beat(4)-17.71%
Max EPS beat(4)97.53%
EPS beat(8)5
Avg EPS beat(8)-26.06%
EPS beat(12)8
Avg EPS beat(12)-11.59%
EPS beat(16)10
Avg EPS beat(16)-6.96%
Revenue beat(2)0
Avg Revenue beat(2)-13.06%
Min Revenue beat(2)-19.5%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-16.01%
Min Revenue beat(4)-27.68%
Max Revenue beat(4)-6.61%
Revenue beat(8)0
Avg Revenue beat(8)-21.76%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.48%
EPS NY rev (1m)-0.84%
EPS NY rev (3m)-7.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.17
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-39.47
EYN/A
EPS(NY)-8.78
Fwd EYN/A
FCF(TTM)-7.46
FCFYN/A
OCF(TTM)-7.39
OCFYN/A
SpS1.12
BVpS19.16
TBVpS19.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.46%
ROE -48.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.27%
FCFM N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.5%
Cap/Sales 5.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.53
Quick Ratio 7.22
Altman-Z -1.78
F-Score5
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)1346.5%
Cap/Depr(5y)20638.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.8%
EPS Next Y99.47%
EPS Next 2Y41.3%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.51%
Revenue Next Year-10.16%
Revenue Next 2Y204.72%
Revenue Next 3Y118.28%
Revenue Next 5YN/A
EBIT growth 1Y13.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.5%
OCF growth 3YN/A
OCF growth 5YN/A

TONIX PHARMACEUTICALS HOLDIN / TNXP FAQ

What is the fundamental rating for TNXP stock?

ChartMill assigns a fundamental rating of 3 / 10 to TNXP.


Can you provide the valuation status for TONIX PHARMACEUTICALS HOLDIN?

ChartMill assigns a valuation rating of 1 / 10 to TONIX PHARMACEUTICALS HOLDIN (TNXP). This can be considered as Overvalued.


How profitable is TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

TONIX PHARMACEUTICALS HOLDIN (TNXP) has a profitability rating of 1 / 10.